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Abstract
Introduction. Determining eligibility criteria for resection is the basis of pancreatic head adenocarcinoma treatment planning, yet the currently used CT scan only has
80% accuracy as its primary modality. This study aimed to investigate preoperative CA 19-9 level use to help predict resectability of pancreatic head adenocarcinoma.
Method. Determining eligibility criteria for resection is the basis of pancreatic head adenocarcinoma treatment planning, yet the currently used CT scan only has 80%
accuracy as its primary modality. This study aimed to investigate preoperative CA 19-9 level use to help predict resectability of pancreatic head adenocarcinoma.
Results. There were 54 subjects enrolled in the study, with the Mean age of both unresectable and resectable subjects is 53.78±11.13 years. Twenty-nine were assigned
as an unresectable group and 25 subjects as a resectable group. We found significant differences in CA 19-9 serum albumin levels and Karnofsky score between the
resectable and unresectable groups. The cut-off point for CA 19-9 levels was 140.65 U/mL, with a sensitivity of 82.76% (64.23% -94.15%), specificity of 72.00%
(50.61% -87.93 %), and AUC of 0.784.
Conclusion. CA 19-9 was significantly associated with eligibility criteria for pancreatic head carcinoma resection. CA 19-9 has a good diagnostic value as an additional
predictor for resectable pancreatic head carcinoma.
Key words: CA 19-9, eligibility criteria for resection, resectable pancreatic head adenocarcinoma

Introduction
Pancreatic head adenocarcinoma is the eleventh highest cause of cancer
mortality which causes 4.5% of all cancer deaths globally. In Indonesia,
pancreatic head adenocarcinoma recorded 4.812 deaths from a total of
4.940 cases in 2018. Surgery is the primary treatment choice for
pancreatic head adenocarcinoma, both for complete resection and as a
primary measure before supportive therapy. Surgery planning for each
case heavily relies on determining the eligibility criteria for
adenocarcinoma resection. These cases were assigned as resectable,
borderline, and unresectable, then later given a treatment plan.1–4
Computerized tomography (CT) scan is currently the most used
modality to determine eligibility criteria for pancreatic head
adenocarcinoma resection through finding the involvement of arteries
and veins in the tumor. This modality shows pancreatic head
adenocarcinoma detection ability with a wide range of sensitivity and
specificity of 70-100%. However, CT scans had limitations, which are
low effectivity in detecting occult peritoneal carcinomatosis, <1 cm liver
metastasis, and occult vascular involvement. These limitations call for
an additional effective modality to assist surgeons in determining
eligibility criteria for pancreatic head adenocarcinoma resection.5–8
Carbohydrate Antigen 19-9 (CA 19-9) is a serum tumor marker
produced by pancreatic cancer exocrine cells, which are detected in the
pancreatic, hepatic, biliary tract, gastric, and ovarium carcinomas.
Although it is not a specific tumor marker, some studies showed that CA
19-9 is helpful for prognostic uses. Including predicting the diagnosis of
resectable pancreatic head adenocarcinoma. A study by Killic et al.
showed that CA 19-9 of 256.6 U/dL referred to an indicator of
unresectable adenocarcinoma, despite CT scan findings.6 However,

Wiguna et al. found the CA 19-9 of 126.76 U/mL as the cutoff level for
resectability, with a sensitivity of 76,9% and specificity of 80%.5
The procedure of treatment relies on being resectable and operable or
not. The resectability is determined by tumor vascularization and the
presence of metastasis. While as, an operable pancreatic head
adenocarcinoma is determined by the patients’ performance status and
laboratory indicator on the Pitts score. These indicators determine
whether the procedure would be intense curative or palliative. Our focus
of interest in this study is to diagnose resectable pancreatic head
adenocarcinoma based on a CT scan. This study aimed to add more
evidence on preoperative CA 19-9 level potential as a predictor for
resectable pancreatic head adenocarcinoma. We also analyzed and
further investigate other patient characteristics that may aid in
determining eligibility criteria for pancreatic head adenocarcinoma
resection.
Method
A cross-sectional study was conducted using the data of all pancreatic
head adenocarcinoma patients in dr. Cipto Mangunkusumo Hospital
enrolled through 2015-2020. The inclusion criteria were those aged ≤65
years, diagnosed histopathologically or by CT imaging, and have
preoperative CA 19-9. A minimum sample size of 49 was calculated
using descriptive categoric sample formula, and 54 samples were
enrolled to avoid inadequate sample size due to dropout.
We collected data from medical records. , including age, gender, body
weight, body height, body mass index (BMI), comorbidity, CA 19-9
levels, Karnofsky performance score, Subjective Global Assessment
(SGA) based on Canadian malnutrition task force score, albumin levels,
bilirubin levels, vascular involvement in tumor determined from CT
scan, resectable or unresectable diagnosis assigned by surgeons in
1
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charge, histopathological findings, and surgery chosen by surgeons in
charge.
All numeric variable was evaluated for distribution normality using
Kolmogorov-Smirnov Test. Bivariate analysis tests were conducted
according to data type and distribution normality using the Unpaired
T/Mann-Whitney test between resectable and unresectable pancreatic
head adenocarcinoma groups. We carried out further diagnostic analysis
for CA 19-9 levels, and the ROC curve was used to determine the cutoff
point. A Chi-square test was used for this purpose. Bias control was done
using multivariate logistic regression analysis of factors with p <0.25 on
bivariate analysis.
This study approved by Ethical Committee of Faculty of Medicine,
Universitas Indonesia, No. KET-1222/UN2.F1/ETIK/PPM.00.02/
2020.

Results
Patient characteristics and diagnostics modalities findings bivariate
analysis
This study included 54 subjects diagnosed with pancreatic head
adenocarcinoma enrolled in dr. Cipto Mangunkusumo General Hospital
through 2016-2020. Twenty-nine subjects were assigned as an
unresectable and 25 subjects as a resectable group through CT scan
imaging. Demographic characteristics, surgical approach is chosen;
laboratory, imaging, and histopathological findings of subjects are
shown in Table 1. The mean age of both unresectable and resectable
subjects is 53.78±11.13 years old.

Table 1. Characteristics of subjects with pancreatic head adenocarcinoma in the study
Unresectable (n= 29)
Age (mean ± SD)
53.83±10.89
Gender [n (%)]
Male
17 (58.62%)
Female
12 (41.38%)
Weight in kg (mean ± SD)
Height in kg (mean ± SD)
Karnofsky score [median (min–max)]
BMI [n (%)]
Underweight
Normoweight
Overweight
Diabetes Mellitus [n (%)]
Scored SGA [n (%)]
A: well-nourished
B: mild/moderately-nourished
C: severely malnourished
Bilirubin in mg/dL [median (min–max)]
Total
Direct
Indirect
CA 19-9 level in U/mL [median (min–max]
Albumin in g/dL [median (min–max)]
Vascular involvement [n (%)]
No involvement
SMV
SMA
CHA
CT
SMA + SMV
Metastasis [n (%)]
Surgery [n (%)]
Biliary stent only
Whipple
Hepaticojejunostomy bypass
Double bypass
Biliary + chemotherapy
PTBD
Metal stent + gastrojejunostomy
Cholecystostomy
Histopathological findings [n (%)]
Adenocarcinoma
Well-differentiated
Moderately differentiated
Poorly differentiated

Resectable (n= 25)
53.72±11.62

p
0.851
0.625

13 (52%)
12 (48%)

53.98±12.39
162.55±7.14
80 (50-100)

54.52±8.64
160.40±7.22
100 (60–100)

14 (48.28%)
14 (48.28%)
1 (3.45%)
2 (6.70%)

2 (8%)
22 (88%)
1 (4%)
4 (16%)

6 (20.69%)
19 (65.52%)
4 (13.79%)

20 (80%)
3 (12%)
2 (8%)

7.02 (0.33–31.21)
5.40 (0.17–22.40)
1.18 (0.12–8.81)
421.9 (25.75–42.648)
3.00 (2.30–4.90)

7.40 (0.34–30.00)
5.40 (0.20–24.90)
2.08 (0.10–17.20)
65 (12–12.000)
3.37 (2.53–4.41)

10 (34.48%)
10 (34.48%)
3 (10.34%)
1 (3.45%)
1 (3.45%)
3 (10.34%)
14 (48.28%)

23 (92%)
2 (12%)
0
0
0
0
0

11 (37.93%)
0
1 (3.45%)
5 (17.24%)
3 (10.34%)
1 (3.45%)
7 (24.14%)
0

8 (32%)
10 (40%)
1 (4%)
2 (8%)
2 (8%)
1 (4%)
0
1 (4%)

21 (72.41%)
6 (20.69%)
2 (6.90%)
0

17 (68%)
6 (24%)
0
2 (8%)

0.277
0.972
<0.001
0.003

0.399
<0.001

0.938
0.896
0.259
<0.001
0.030

<0.001

<0.001

0.301

0.696

Abbreviations: BMI= Body Mass Index, SGA= Subjective Global Assessment based on Canadian malnutrition task force (CMTF), SMV= Superior mesenteric
vein, SMA= Superior mesenteric artery, CHA= Common hepatic artery, CA= Celiac artery, PTBD= Percutaneous transhepatic biliary drainage.
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Bivariate analysis showed significant difference between unresectable
and resectable groups for CA 19-9 (p <0.001), Karnofsky score (p
<0.001), BMI (p = 0.003), SGA score (p <0.001), serum albumin (p =
0.030), vascular involvement (p <0.001), and metastasis (p <0.001).
These variables were then included in multivariate logistic regression
analysis for bias control, except for vascular involvements and
metastasis, as these parameters were used as a gold standard basis in
assigning groups for subjects. Before multivariate analysis, numerical
variables (albumin and Karnofsky score) were dichotomized using the
area under the curve (AUC)-ROC curve to find the cutoff level. The
result was 3.025 g/dL optimum level of albumin (sensitivity of 76% and
specificity of 62.1%) and 85 values cut off for Karnofsky score
(sensitivity of 80% and specificity of 69%).

Table 3. Proportion analysis of CA 19-9 between resectable and unresectable
group
Group
CA 19-9
p
Unresectable
Resectable
OR (CI 95%)
(U/mL)
n (%)
n (%)
≥140.65
24 (82.76)
7 (14)
12.34
0.000*
(3.4–45.3)
<140.65
5 (17.24)
18 (76)
Total
29
25
*Chi-square test

Preoperative CA 19-9 levels and eligibility criteria for pancreatic
head adenocarcinoma resection

This study found a statistically significant difference in Karnofsky score,
BMI, SGA score, and albumin value. This finding may be related to the
eligibility criteria for pancreatic head adenocarcinoma resection affected
by malignancy stages, which would directly affect these factors. We also
found elevated bilirubin levels in 86% of patients caused by CBD
compression on the first stages of pancreatic head adenocarcinoma. Out
of 25 resectable patients, only 10 (40%) could receive tumor resection
procedure (Whipple procedure). This number may be related to the fast
progression of adenocarcinoma and negative biliary drainage response,
explaining why 60% of patients whose predicted as resectable through
radiological modality were deemed inoperable before surgery.13

This study recorded a 2698.40 ± 6843.33 U/mL mean level of CA 19-9
with some outlier data. The preoperative CA, 19-9 level of study
subjects, are shown in Table 1, in which bivariate analysis using MannWhitney test showed significant difference for Ca-19-9 level between
resectable and unresectable group (p <0.001). We developed a ROC
curve to find the AUC value and determine the CA 19-9 cutoff level
with optimum sensitivity and specificity to predict resectable pancreatic
head adenocarcinoma, as shown in Figure 1. The study found 0.784
AUC (SD = 0.065; CI (95%) = 0.656-0.912; p <0.001). ROC curve
showed the CA 19-9 cutoff level was 140.65 U/mL with the sensitivity
of 82.76% (64.23%-84.15%) and specificity of 72.00% (50-61%87.93%) as described in Table 2.

Figure 1. AUC-ROC curve for preoperative CA 19-9 level use in
predicting resectable pancreatic head adenocarcinoma.

Table 2. Diagnostic Value of CA 19-9 level on 140.65 U/mL threshold as
additional eligibility criteria for pancreatic head adenocarcinoma resection
Parameter
Value
CI (95%)
Sensitivity
82.76%
64.23%–94.15%
Specificity
72.00%
50.61%–87.93%
Positive predictive value
77.42%
64.15%–86.79%
Negative predictive value

78.26%

60.99%–89.23%

Positive likelihood ratio

2.96

1.54–5.66

Negative likelihood ratio

0.24

0.10–0.55

Further analysis found the difference between preoperative CA 19-9
between unresectable and resectable pancreatic head adenocarcinoma
groups using the determined optimum CA 19-9 cut–off level. The Chisquare test showed a significant difference between the resectable and
unresectable groups, as shown in Table 3.

Discussion
Subject Characteristics

Diagnostic value of CA 19-9 to predict resectable pancreatic head
adenocarcinoma
Prior studies had shown the potentials of preoperative CA 19-9 level as
prognostic predictor pancreatic adenocarcinoma, as Dong et al.14 found
>338.45 U/mL CA 19-9 level predicted a low one-year survival rate
with a sensitivity of 60% and specificity of 66.7%. Following prognostic
predictions, eligibility criteria for pancreatic head adenocarcinoma
resection depend on adenocarcinoma cells infiltration to nearby tissue,
in which a higher rate of infiltration would be reflected by a higher level
of CA 19-9. This study demonstrated that CA 19-9 level could predict
resectable pancreatic head adenocarcinoma accuracy up to the
appropriate category.13,15
This result was contradictive with Pandiaraja et al.4 study, which
mentioned no relationship between CA 19-9 level and resectable
pancreatic head adenocarcinoma; but Pandiaraja et al. used 37 U/mL
CA 19-9 level as the optimum level, which was much lower than the
optimum CA 19-9 level used in our study. Their study also failed to
mention the obtained sensitivity and specificity from their analysis. Our
study result was supported by other studies, such as Killic et al. [6] that
found 256.4 U/mL CA 19-9 cut-off level with 82.4% sensitivity, 92.3%
specificity, and 0.892 AUC. We believe the variation of sensitivity,
specificity, and AUC value with our study was caused by the difference
in patients' characteristics.
There haven't been many studies that evaluated CA 19-9 diagnostics
values, as most studies focused on elevating the accuracy of CT scans.
The use of CT scan is deemed easier and more efficient, but it should be
noted that the availability of CT scan in Indonesia is scarce, so a more
straightforward method using laboratory findings remains needed.
Multivariate analysis with logistic regressions
Different characteristics of patients may contribute to the interpretation
of diagnostic modalities result, and there may be some confounding
factors that work against the interpretation of the diagnostics modalities'
sensitivity, specificity, and AUC value. We included various dependent
variables other than CA 19-9 levels to test this possibility and found
3
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Karnofsky score and albumin levels to affect resectable pancreatic head
adenocarcinoma prediction. We tried to combine these factors with CA
19-9 levels and found elevated diagnostic value for CA 19-9 levels into
an excellent category when combined with Karnofsky score and
albumin levels.
Although the Karnofsky score is a clinical indicator and albumin has no
specific link with the natural history of pancreatic head adenocarcinoma,
both variables are commonly used to predict adequate physical
condition before surgery and contributed to predicting operability. Thus,
we believe these factors could be potential predictors of a patient's
clinical prognosis post-surgery. No study has examined this possibility
yet, and further study is needed to understand these variables' value as
additional eligibility criteria for pancreatic head adenocarcinoma
resection.15
Conclusion
There was a significant association between preoperative CA 19-9 and
eligibility criteria for pancreatic head adenocarcinoma resection. There
was also a significant difference in albumin levels and Karnofsky scores
between the resectable and unresectable groups. Further studies with
more samples from different healthcare settings are needed to evaluate
CA 19-9 levels' prognostic values and possibly use combined indicators
with albumin level and Karnofsky score.
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